Scientists Design a Potent Pill-Form GLP-1 Drug Using Computer-Aided Drug Design | Research

The takeaway

Rational design with computer-aided drug design identified a novel small molecule GLP-1R agonist with robust in vitro and in vivo efficacy, potentially enabling an oral pill alternative to injectable GLP-1 drugs.

Unique binding mode
Compound 6 activates GLP-1R through a novel mechanism different from peptide agonists

What the researchers found

Compound 6, designed through rational CADD approaches, showed a unique GLP-1R binding mode and robust efficacy in both in vitro and in vivo models as a small molecule agonist.

Why it matters

Most GLP-1 drugs require weekly injections that many patients resist. A potent oral pill with the same benefits would dramatically expand treatment access and adherence for diabetes and obesity.

How the study worked

Rational drug design with computer-aided drug design (CADD); in vitro receptor binding and activation assays; in vivo animal efficacy studies.

What this study cannot tell us

Preclinical data only — human trials needed; oral bioavailability and safety profile require further optimization; small molecule may have different side effect profile than peptide-based drugs.

How to read the evidence

Preclinical drug discovery — strong in vitro and in vivo data but no human data yet.

When this study was published

Published in 2026, at the forefront of small molecule GLP-1R agonist development.

The bigger picture

The race to develop oral GLP-1 drugs is one of pharma's biggest priorities. A truly potent small molecule agonist could make GLP-1 therapy as simple as taking a daily pill, potentially helping hundreds of millions of people.

Questions still open

How does compound 6's efficacy compare to injectable semaglutide in head-to-head preclinical testing?
Can the unique binding mode avoid the GI side effects common with peptide GLP-1 drugs?

Common questions

Could this become an Ozempic pill?

Potentially — if this small molecule GLP-1 agonist proves safe and effective in human trials, it could offer the same benefits as injectable semaglutide in a convenient daily pill form.

Why is making an oral GLP-1 drug so hard?

GLP-1 is a peptide that gets destroyed by stomach acid. Small molecule drugs that mimic GLP-1's effects without being peptides are extremely difficult to design because the GLP-1 receptor is complex and usually needs large molecules to activate it.

Read the original research

A potent novel small molecule GLP-1R agonist identified by rational design and CADD.

Bioorganic & medicinal chemistry, 136, 118578

View on PubMed ↗Publisher’s paper ↗

Citation

Chen, Jiayu; Yao, Yuanshan; Li, Hao. (2026). A potent novel small molecule GLP-1R agonist identified by rational design and CADD.. Bioorganic & medicinal chemistry, 136, 118578. https://doi.org/10.1016/j.bmc.2026.118578